China Universal Asset Management Company’s Rapport Therapeutics RAPP Stock Holding History

China Universal Asset Management Company’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$451K	Sell	10,812 -1,246	-10%	-$45.8K	0.03%	273
2026 Q1	$377K	Buy	12,058 +1,292	+12%	+$36.3K	0.03%	288
2025 Q4	$327K	Buy	10,766 +3,368	+46%	+$93.2K	0.03%	293
2025 Q3	$220K	Buy	7,398 +68	+0.9%	+$1.21K	0.02%	327
2025 Q2	$83.3K	Sell	7,330 -7	-0.1%	-$74	0.01%	378
2025 Q1	$73.6K	Sell	7,337 -419	-5%	-$5.44K	0.01%	387
2024 Q4	$138K	Buy	+7,756	New	+$172K	0.01%	361

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

China Universal Asset Management Company's RAPP Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Rapport Therapeutics (RAPP) stake by 10% in Q2 2026, selling an estimated $45.8K and leaving 10,812 shares worth $451K. The position accounts for 0.03% of the portfolio, ranked #273.

China Universal Asset Management Company first reported a position in RAPP in Q4 2024 and has held it in 7 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

China Universal Asset Management Company held 10,812 shares of Rapport Therapeutics worth $451K as of Q2 2026.
China Universal Asset Management Company sold 1,246 Rapport Therapeutics shares in Q2 2026, an estimated $45.8K.
Rapport Therapeutics made up 0.03% of China Universal Asset Management Company's portfolio in Q2 2026, its #273 holding.
China Universal Asset Management Company first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 7 quarters since.
161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.